7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …

Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …

Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …

Lung cancer is primarily diagnosed during the advanced stage of disease, at which stage
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to
occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of …

7160 Background: The HER1/EGFR inhibitor erlotinib significantly prolongs survival of
patients with previously-treated advanced NSCLC. Methods for selecting patients most likely …

Erlotinib has been shown to prolong progression‐free (PFS) and overall survival (OS) in
patients with advanced non‐small cell lung cancer (NSCLC). We report here on …

Abstract Treatment of non-small-cell lung cancer is dependent on disease stage. For
patients with metastasis or locally advanced disease, the importance of finding therapeutic …